(1R,3R)-3-(benzyloxycarbonylamino)cyclohexanecarboxylic acid | 1035325-24-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1R,3R)-3-(benzyloxycarbonylamino)cyclohexanecarboxylic acid
• 英文别名: (1R,3R)-3-(((Benzyloxy)carbonyl)amino)cyclohexanecarboxylic acid；(1R,3R)-3-(phenylmethoxycarbonylamino)cyclohexane-1-carboxylic acid
• CAS: 1035325-24-6
• 化学式: C₁₅H₁₉NO₄
• 分子量: 277.32
• InChiKey: LTEORMGXUMWZCU-CHWSQXEVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1R,3R)-3-(benzyloxycarbonylamino)cyclohexanecarboxylic acid 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 三乙胺 、 cesium fluoride 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 benzyl N-[(1R,3R)-3-[(6-allyl-3-chloropyrazin-2-yl)methylcarbamoyl]cyclohexyl]carbamate
  参考文献：
  名称：

  [EN] REVERSIBLE MACROCYCLIC KINASE INHIBITORS
  [FR] INHIBITEURS DE KINASE RÉVERSIBLES MACROCYCLIQUES

  摘要：

  The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicament, in particular for the treatment specific kinase mediated disorders, such as cancer.

  公开号：

  WO2023110936A1
• 作为产物：
  描述：

  methyl (1R,3R)-3-(benzyloxycarbonylamino)cyclohexanecarboxylate 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 以800 mg的产率得到(1R,3R)-3-(benzyloxycarbonylamino)cyclohexanecarboxylic acid
  参考文献：
  名称：

  [EN] REVERSIBLE MACROCYCLIC KINASE INHIBITORS
  [FR] INHIBITEURS DE KINASE RÉVERSIBLES MACROCYCLIQUES

  摘要：

  The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicament, in particular for the treatment specific kinase mediated disorders, such as cancer.

  公开号：

  WO2023110936A1

文献信息

• BTK INHIBITORS
  申请人：De Man Adrianus Petrus Antonius

  公开号：US20140221333A1

  公开（公告）日：2014-08-07

  Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

  提供了式(I)所示的6-5元融合吡啶环化合物或其药学上可接受的盐，以及包含这些化合物的药物组合物及其在治疗中的用途。特别地，提供了使用融合吡啶环化合物治疗布鲁顿酪氨酸激酶（Btk）介导的疾病的用途。
• US9718828B2
  申请人：——

  公开号：US9718828B2

  公开（公告）日：2017-08-01
• [EN] REVERSIBLE MACROCYCLIC KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE RÉVERSIBLES MACROCYCLIQUES
  申请人：[en]NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V

  公开号：WO2023110936A1

  公开（公告）日：2023-06-22

  The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicament, in particular for the treatment specific kinase mediated disorders, such as cancer.